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CHAPTER 1- INTRODUCTION AND BRIEF HISTORICAL NOTE

The evolution of care concerning end-stage renal disease (ESRD) has been a multilayered, multi-faceted one. Thomas Graham, the nineteenth century Scottish scientist who was
best known for his pioneering work in the area of colloid chemistry, helped to establish
principles of gas exchange (Graham’s law) that were later incorporated into Willem Kolff’s 1944
dialysis machine which was touted as the “first artificial kidney” [1, 2]. Despite the tremendous
early success of hemodialysis, it would soon be supplanted as the preferred treatment for ESRD
by a modality that had begun its quiet parallel development in Austria at the turn of the twentieth
century. This modality was renal transplantation. Renal transplantation began in 1902 with the
first successful animal-to-animal kidney transfer [3].

By 1909, the first human

xenotransplantation had been conducted in France and despite the fact that it only functioned for
one hour, it represented a huge clinical leap [4]. 1949 proved to be a milestone year in the
growth of the fledgling discipline of renal transplantation, during which Sir Peter Medawar, a
British zoologist, described acquired immune tolerance and the immunology of organ rejection
for which he was later awarded the Nobel Prize [5, 6]. On the heels of this immunologic
understanding, Joseph E. Murray performed the first truly successful kidney transplantation
between identical twins in 1954 followed shortly by the first successful cadaveric kidney
transplantation in 1962 performed by Samuel Kountz and Roy Cohn at Stanford University. For
their contributions these men were held in high regard and like Medawar many years prior,
Murray was awarded the Nobel Prize in 1990 for his contributions to transplantation medicine
[7]. The next three decades would be embossed by advances in immunosuppressive therapy,
with the inclusion of steroids (1963), azathioprine (1963), cyclosporine (1972), and
mycophenolate mofetil (1995). This period would also mark the passage of the End Stage Renal
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Disease Act (1972), which assured medical coverage for all patients with ESRD and would later
be extended to cover transplantation expenses as well [8]. The benefits of the aforementioned
advances would soon translate into improved patient survival. In 1973, an article published in the
Journal of the American Medical Association reported on outcomes of 10,357 of the 12,389
transplants that were performed from 1951 to 1970. In this article, they noted that patient
survival was 47.6% [9]. However, just 10 years later in 1983 the nationwide 1 year patient and
graft survival had improved to 95% and 88%, respectively [10, 11]. With this new outcome data
demonstrating the efficacy and potential promise of renal transplantation, it officially replaced
hemodialysis as the preferred treatment for ESRD. Over the next decade (1990-2000), the
growth of renal transplantation was substantial, increasing from approximately 7000 kidneys
transplanted per year to 12,000 in the US. [12]. In addition, the emerging clinical innovations in
immunosuppressive therapy, multidisciplinary treatment protocols, and surgical management
helped to redefine the selection criteria for both renal allograft donors and recipients. Recipients
who were once considered to be too high risk were now representing a sizable part of annual
totals at many transplant centers [13, 14]. With more patients now being considered for renal
transplantation, the disparity between the supply of available grafts and the demand has been
exacerbated [15]. Organ Procurement and Transplantation Network data collected from January
to August 2009 reported that there were 105,127 individuals on the waiting list for kidney
transplants. For this same period, there were only 19,114 combined deceased- and live-donor
grafts available [15]. In the face of this growing organ shortage, many efforts have been
launched to mitigate this disparity. Some of these have included Organ Procurement
Organization and United Network for Organ Sharing campaigns to educate the public about
minimally invasive (laparoscopic) live-donor options as well as driver’s license-based organ
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donation programs [16, 17]. Despite these notable efforts, the organ supply simply has not kept
pace with the demand. This is especially true when considering that the incidence of the major
causes of ESRD (i.e. hypertension and diabetes) are on the rise [18, 19]. Based upon these
observations, preservation of existing graft function and graft survival must be of paramount
importance.
The research contained within this document is aimed at addressing acute rejection (AR)
and the persistent threat that it poses to graft function and survival. It accomplishes this by
presenting a foundational study regarding the development of a noninvasive method of detecting
acute renal allograft rejection based upon the laser-based technological tool, Raman spectroscopy
(RS).
The organizational structure of chapters 2 through 4 is designed to provide a working
knowledge of transplant immunology and RS as well as familiarize the reader with a
comprehensive review of the major non-Raman-based, noninvasive methodologies to detect AR
that have been proposed to date. In addition, these chapters serve to outline the scope of the AR
problem by highlighting the limitations of the current screening modality. Chapters 5 through 7
describe the experimental design, results, and conclusions for the various studies that were
conducted to support our hypothesis that RS can effectively model T lymphocyte activation and
serve as an eventual tool to noninvasively diagnose AR with high accuracy. Chapters 5 through 7
are each organized to present data that pertain to a particular investigational question. As a
group, chapters 5 through 7 provide a three-pronged research approach to support the
aforementioned hypothesis. This organizational theme allows improved flow of content and
affords an intellectual structure for chapter 8 which comprehensively discusses the results of
chapters 5 through 7 and draws all concepts contained herein to a global conclusion.
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CHAPTER 2- CLINICAL AND IMMUNOLOGICAL BACKGROUND
2.1- Immunologic Overview
In order to gain a better understanding of the mechanisms driving organ rejection and
how RS can be used in its detection, a brief review of the immune system is in order. The
immune system is comprised of several cellular and non-cellular components and is organized
with respect to function in response to a foreign antigen or pathogen. It can be divided into the
innate and adaptive immune systems [1].
The innate immune system is the initial responder to foreign antigens. The role of this
system is to contain, mitigate, and if possible, eliminate the pathogen/antigen within the first 2-3
days following infection/pathogen introduction [1].

The innate immune system can be

subdivided into barrier, neutralization, and elimination components. The barrier components
consist of the skin and mucous, which are crucial to maintaining an effective partition to the
external environment. The neutralization and elimination of foreign antigens is carried out by
polymorphonuclear cells (PMN; also known as neutrophils), natural killer cells (NKC), dendritic
cells, macrophages, eosinophils, mast cells, and to a lesser extent, basophils. In addition, innate
immunity utilizes the complement system. This system of factors and enzymes is involved in
coating the surface of pathogens thus making them more susceptible to phagocytosis, cell lysis,
and elimination [1].
The adaptive immune response is tailored according to the particular type of pathogen
that is present. Unlike the innate immune system which is initiated immediately, the adaptive
immune system requires 5-10 days to mount a full response to a primary infection or
introduction to foreign antigen. This response is carried out through the actions of B and T

8

lymphocytes. A summary of how the two aforementioned divisions of the immune system are
organized is depicted in figure 1.

Figure 1. Organizational scheme of the adaptive and innate cells of the immune system [1].
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B lymphocytes are primed and activated by T lymphocytes. These activated forms of B
lymphocytes are called plasma cells which are capable of producing and releasing antibodies or
immunoglobulins (Igs). There are five classes of Igs; IgG, IgA, IgM, IgD, and IgE [1]. These Igs
possess a conserved Fc region and a variable Fab domain. This variable Fab domain allows each
Ig to take on over 1014 different structural forms [2]. These Igs aid in the neutralization process
by coating and tagging the foreign antigen for elimination. Igs can also act directly on infected
cells using a complement directed membrane attack complex that results in holes being placed in
the membrane leading to cell lysis [2].
The T lymphocyte makes up about 80% of the total circulating lymphocytes [1].
Structurally, the T cell receptor (TCR) has a similar structure to the Fab portion of the Ig [2]. The
heterodimeric receptor has both an alpha (α) and beta (β) subunit which is composed of Nterminal Ig variable domain, one Ig-constant domain, a transmembrane/cell membrane-spanning
region, and a short cytoplasmic tail at the C-terminal end [3]. The N-terminal variable domains
of both the TCR α-chain and β-chain have three complementarity determining regions (CDRs),
CDR1, CDR2, and CDR3. These CDRs are hyper-variable regions which allow myriads of
possible antigen binding combinations. There is an additional variable region of the β-chain
(HV4) which also has a hyper-variability region. However, this HV4 region does not normally
contact major histocompatibility complex (MHC)-bound peptide antigens but is essential in the
binding of non-specific and superantigens (i.e. CD3/CD28-coated activation beads and mitogens,
respectively) [3]. These residues are situated at the interface of the α- and β-chains and in the βchain framework which is thought to be involved in binding the CD3 complex. The CDR that is
responsible for the majority of antigen recognition is the CDR3. CDR1 of the α chain interacts
with the N- terminus of the antigen peptide whereas the CDR1 of the β chain is involved in
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binding the C- terminus of the antigen peptide. CDR2 is thought to recognize the MHC [3].
T lymphocytes express either CD4 or CD8. These cell surface molecular subtypes are
derived from a differentiation process that occurs in the thymus early in immunologic
development. This process designates CD4+ cells as T helper lymphocytes and CD8+ cells as
cytotoxic T lymphocytes. T lymphocytes work intimately with antigen presenting cells (APCs)
of the innate immune system, which are specialized cells capable of phagocytosis of foreign
antigens. These antigens are processed and presented to the T lymphocyte via the highly
conserved cell surface molecule, the MHC. There are two classes of MHC molecules, designated
I and II. Class I MHCs are found on all nucleated cells, whereas only cells that possess
phagocytotic properties (i.e. dendritic cells, macrophages, PMNs, B lymphocytes) co-express
MHC class II molecules. MHC class I and II molecule interact with the TCR of CD4+ and
CD8+, respectively. This interaction is termed signal 1. Signal 1 leads to T lymphocyte
activation and clonal expansion only in the presence of the co-stimulatory feedback, signal 2.
This involves the T cell’s CD28 binding to the APC’s CD80. In the absence of signal 2 the T
lymphocyte undergoes anergy and is prevented from activating (Figure 2) [4].
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APC
Signal 1
Signal 2

Figure 2. The binding of TCR- MHC complex (signal 1) and CD28-CD80 complex (signal 2) leading to T cell
activation or in the absence of signal 2, anergy [4].
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In the presence of a proper signal 1 and 2 the T lymphocyte is activated. For this research
investigation, T lymphocyte activation was defined as an increase in immune-specific DNA
transcription/translation, dimerization of CD3 with the TCR, and the characteristic upregulation of cell surface receptors, notably CD69, CD25, and CD71 [1, 5-7].
The mechanisms of these activation events begin with the binding of a ligand (MHC) to
the TCR which is followed by CD3, CD4, and TCR clustering. This is facilitated by
phosphorylation of tyrosine residues on the cytosolic face of the plasma membrane [8]. This
initial tyrosine kinase-driven step is common to all forms of activation regardless of the
particular ligand or stimulus. Initial receptor clustering is followed by phosphorylation of zeta
chain-associated protein kinase 70 (Zap-70) which in turn phosphorylates phospholipase C- γ
(PLC). PLC leads to three important activation pathways. The first involves the activation of
guanine-nucleotide exchange factor which results in the activation of mitogen activated protein
(MAP) kinase and ultimately the activator protein-1 (AP-1) transcription factor. The second
pathway activated by PLC leads to the cleavage of phosphatidylinositol bisphosphate (PIP2) to
yield diacylglycerol (DAG). DAG and Ca2+ activate protein kinase C culminating in the
activation of the transcription factor, NF kappa B. The third pathway begins with PLC cleaving
PIP2 into inositol triphoshate (IP3). IP3 increases cytosolic calcium levels activating calcineurin
which works directly to increase the activity of nuclear factor of activated T cells (NFAT). The
main transcription factors from all three pathways (AP-1, NF kappa B, and NFAT) lead to an
increase in immune-related gene transcription, cell proliferation, and differentiation [8]. Figure 3
summarizes these activation events.
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Figure 3. T lymphocyte intracellular activation pathway [9].
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A key step in the aforementioned early activation process is the clustering and subsequent
binding of CD3 with the TCR (Figure 4). CD3 is present at low levels on the surface of nonactivated T lymphocytes [1]. The binding of the MHC to the TCR triggers intracellular activation
of LcK and Zap-70 which phosphorylates the cytoplasmic tails of CD3 resulting in assembly of
its subunits. This CD3 complex then binds the TCR leading to a conformational change in the 3
dimensional (3D) structure of the TCR-MHC union (Figure 5). It is important to note that even
when the MHC is released from the TCR-CD3 complex, the TCR-CD3 complex remains at a
different conformational state and 3D structure than the un-stimulated TCR and non-clustered
CD3 subunits [10,11].

Figure 4. Dimerization of CD3 complex and TCR is necessary for T lymphocyte activation [10].
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Figure 5. Conformational change in the TCR-MHC union before (A) and after (B) CD3 binding. There is
significant alteration in 3D structure of the TCR noted in the superior aspect of the diagram. Antigen peptide shown
in pink; anchor protein (MHC II) and stabilizing protein (CD3) are shown in red [11].

This conformational change is not only essential to the initiation of the intracellular
activation cascade, but also significantly alters the exposed molecular residues on the T cell
surface transforming the topographic profile involved in light scattering. These surface changes
are amplified by the addition of the up-regulated CD25, CD69, and CD71 receptors. In fact,
there are over 1018 structurally different receptors on the surface of activated T lymphocytes, as
compared to its non-activated counterparts [12]. It is this specialized up-regulation of cell surface
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receptors and subsequent change in molecular topography that provides the key to identifying
activated T lymphocytes using RS.
2.2- The Immunologic Basis of Renal Allograft Rejection
Allograft rejection can be divided into three main categories; hyperacute, acute, and
chronic rejection. This classification is based on the timing and nature of histopathologic changes
in the transplanted organ as well as the particular biologic component of the immune system that
drives the process. It is important to note that these rejection processes are not discretely separate
events. Instead, they exist on a continuum of immunologic response to foreign allograft antigens.
Hyperacute rejection is caused by preformed antibodies in the recipient directed toward
the endothelium of the donor graft [13]. These antibodies bind to the vascular endothelium
activating the complement and clotting cascades which result in obstruction of graft vessels,
parenchymal congestion, and death of the graft within minutes (Figure 6) [13]. Fortunately, this
irreversible process is rare due to the routine use of prospective cytotoxic crossmatching which
screens for the preformed antibodies [14].

Figure 6. Gross specimen of kidney illustrating hyperacute rejection with focal areas of infarction (arrow) [12].
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Chronic rejection remains a poorly understood inflammatory process that has many
immunologic and non-immunologic causes including, but not limited to, ischemic-reperfusion
injury, cytomegalovirus (CMV) infection, multiple episodes of AR, and calcineurin
inhibitor/sirolimus toxicity [15]. The pathohistologic findings can be characterized by concentric
atherosclerosis of vessels coupled with glomerulo-tubular fibrosis and atrophy [16, 17]. The
predominant cell found within graft vessels and tissues late in chronic rejection is the
macrophage [1]. These cells are attracted by chemokines that cause the maturation of monocytes
(the immature blood-dwelling form of macrophages) and their infiltration into tissues via
endothelial adhesion molecules. Once in the tissues, macrophages secrete high levels of IL-1 and
TNF-α which lead to further macrophage recruitment [1]. The result of this inflammatory
activity is progressive nephron fibrosis often termed chronic allograft nephropathy (CAN) [17].
The activated T lymphocyte is both necessary and sufficient to induce AR [1]. Whether it
is the recognition of non-self via foreign MHC class I molecules in the periphery by CD8+
cytotoxic T cells or the interrogation of graft-derived foreign APCs in host lymph nodes by
CD4+ helper T cells, the activated T lymphocyte is central to the initiation of a immunological
cascade culminating in renal allograft destruction in the acute setting [1]. The histopathologic
findings of AR range from foci of moderate tubulitis to severe intimal arteritis with focal
infarction, depending on the severity or grade. The particular grades of AR are described by the
Banff 97 criteria and are illustrated in Appendix A [18].
2.3- Clinical Implications of Allograft Rejection
AR can cause graft dysfunction and on occasions, complete graft loss [19, 20]. AR most
commonly occurs within the first 6 months following transplantation. The incidence of AR
ranges from 3% to 22% and is dependent upon the individual transplant center, source of graft
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(deceased vs. live donor), panel reactive antibody levels, and recipient risk factors [21, 22].
Moreover, it has been well documented that African Americans, pediatric, and retransplant
patients have a higher incidence of AR when compared with their Caucasian, adult, primary
transplant counterparts [22].

The negative clinical impact of AR on graft outcomes has also

been well described. In a study looking at deceased-donor renal allografts transplanted over a 7
year period, it was reported that the half-life of the graft increased from 7.0 to 17.9 years in the
absence of current or previously reported AR episodes. On the other hand, grafts that had one or
more reported episodes showed only a marginal increase in half-life from 7.0 to 8.8 years over
the same time period [23]. This data suggests that although AR is reversible in most cases, its
occurrence, severity, and timing negatively affect graft survival. Clearly, the earlier that
adjustments to the immunosuppressive regiment aimed at reversing the episode can be made, the
better the subsequent functional result. However, this early diagnosis is difficult with current
modalities. Reliable screening for AR has proven problematic due its deceptively benign
presentation as an asymptomatic elevation in serum creatinine. This abnormal increase in serum
creatinine of 25% or greater compared with a post-transplant baseline is used by most centers as
a marker for AR [24].

Despite its routine usage, serum creatinine elevation is a late finding

which manifests only after rejection has been present long enough to cause significant histologic
damage to nephrons leading to disruption in renal function and a subsequent decrease in
clearance. In addition to being a late finding of AR, elevations in serum creatinine have a low
sensitivity, since subclinical AR (SCAR) can occur with no detectable change in serum
creatinine [25]. SCAR has prompted a greater implementation of protocol renal transplant
biopsies in response to concerns over the accelerated development of CAN if the condition
remains undetected and untreated [26, 27].

Moreover, serum creatinine lacks specificity as a
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marker, largely due to the observation that urinary tract infections, abnormal blood glucose
levels, and dehydration can cause false positives [28]. Even immunosuppressive medications,
mainly tacrolimus and cyclosporine, can lead to nephrotoxicity which clinically presents as
elevations in serum creatinine [14]. This late, non-sensitive, non-specific modality of detecting
AR has also prompted many patients to undergo unnecessary biopsies. These biopsies come with
the risks of pain, bleeding, infection, creation of artereriovenous fistulae, and in rare cases loss of
graft [29, 30]. Coupled with the risks posed to patients, biopsies are subject to sampling errors
and represent a significant financial burden on the health care system [31].

Based upon the

limitations of the current screening modality for AR, a rapid, noninvasive screening tool that
provides both a high sensitivity and specificity is highly desirable.

20

REFERENCES
1. Janeway C, Travers P, Walport M, Capra J. 1999. Immunobiology: The immune
system in health and disease. 4th edition. Garland Publishing, NY. p. 294-298.
2. Litman G, Rast J, Shamblott M (1993). "Phylogenetic diversification of
immunoglobulin genes and the antibody repertoire". Mol. Biol. Evol. 10 (1): 60–72
3. Kieke M, Shusta E, Teyton L, Wittrup D, Kranz D. "Selection of functional T cell
receptor mutants from a yeast surface-display library", Proceedings of the National
Academy of Science of the United States of America 96 (10): 5651–5656
4. Adapted from: Olsson M, Hagnerud S, Hedelius D, Oldenborg P . Hematologic
Diseases: Autoimmune Hemolytic Anemia and Immune Thrombocytopenic Purpura.
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=eurekah&part=A36437.
5. Bernard A, Boumsell L, Hill C. 1984. Joint report of the first international workshop
on human leucocyte differentiation antigens by the investigators of the participating
laboratories. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, eds.
Leucocyte Typing. New York, NY: Springer-Verlag. 9-108.
6. Chen J, Prince H, Buck D, et al. 1988. Leu-23: an early activation antigen on human
lymphocytes. Fed Proc 2:A1214.
7. Testi R, Philips J, Lanier L. 1989. Leu-23 induction as an early marker for functional
CD3/T cell antigen receptor triggering: requirement for receptor cross-linking,
prolonged elevation of intracellular (Ca++), and stimulation of protein kinase C. J
Immunol 142:1854.

21

8. Signaling through immune system receptors. Immunobiology. NCBI Bookshelf.
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=imm&part=A673. 1/2/2010.
9. Adapted from: Robert T. Abraham & Arthur Weiss. Jurkat T cells and development
of the T-cell receptor signaling paradigm. Nature Reviews Immunology 4, 301-308
(April 2004) and Linsley PS, Ledbetter JA. The role of the CD28 receptor during T
cell responses to antigen. Annu Rev Immunol. 1993; 11: 191–212.
10. Kjer-Nielsen L, Dunstone M, Kostenko L, Ely L, Beddoe T, Mifsud N, et al. 2004.
Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the
therapeutic mAb OKT3. PNAS 101(20). P 7675-7680.
11. Adapted from: Kaas and Lefranc, In Silico Biol. 5, 0046 (2005).
12. http://uhaweb.hartford.edu/BUGL/immune.htm#adapt (2002)
13. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Bühler R, Vaughan RW,
O'Donnell PJ, Snowden SA, Bewick M, Hendry BM. 1996. Prevention of hyperacute
rejection by removal of antibodies to HLA immediately before renal transplantation.
Lancet 348(9036):1208-1211.
14. Janeway C. Travers P. Walport M. Capra J. 1999. T Cell Mediated Immunity. In:
Austin, P., Lawrence, E. Immunobiology: The immune system in health and disease
4th edition. Garland Publishing, NY. p. 515-519.
15. Paramesh A, Grosskreutz F, Sander S, GondolesiG. Sharma, et. al. 2004. Thrombotic
microangiopathy

associated

with

combined

sirolimus

and

tacrolimus

22

immunosuppression after intestinal transplantation. Transplantation 77(1): p. 129131.
16. Nankivell B, Borrows R, Fung C, O'Connell P, Allen R, Chapman J. 2003. The
Natural History of Chronic Allograft Nephropathy. NEJM 349:2326-2333.
17. Freese P, Svalander C, Mölne J, Nordén G, Nyberg G. 2001. Chronic allograft
nephropathy- biopsy findings and outcome. Nephrol Dial Transplant 16: 2401-2406.
18. Bogman M and Dooper M. 1995. Banff classification for the histologic diagnosis of
renal graft rejection: what are the advantages? Nephrol Dial Transplant: Editorial
comments: p. 1291-1293.
19. Cosio FG, Pelletier RP, Falkenhain ME, Elkhammas EA, Davies EA, Bumgardner
GL, Ferguson RM. 1997. Impact of acute rejection and early allograft function on
renal allograft survival. Transplantation 63: 1611.
20. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM. 1993. Predictors of long-term
primary cadaveric renal transplant survival. Clin Transplant 7: 345.
21. Meier-Kriesche HU, Ojo A, Magee J, Cibrik D, Hanson J, Leichtman A, and Kaplan
Bruce. 2000. African-American renal transplant experience decreased risk of death
due to

infection:

possible implications

for immunosuppressive

strategies.

Transplantation 70 (2). p. 375-379.
22. Hardinger K, Stratta R, Egidi F, et al. 2001. Renal allograft outcomes in African
American versus Caucasian transplant recipients in the tacrolimus era. Surgery 130.
(4).

23

23. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D.
2000. Improved graft survival after renal transplantation in the United States, 1988 to
1996. N Engl J Med 342:605.
24. Gaber LW, Moore LW, Alloway RR, Flax SD, Shokouh-Amiri MH, Schroder T,
Gaber AO. 1996. Correlation between Banff classification, acute renal rejection
scores and reversal of rejection. Kidney Int 49 (2): p. 481-487.
25. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RD, Chapman JR. 2004.
Natural history, risk factors and impact of subclinical rejection in kidney
transplantation. Transplantation 78: p. 242-249.
26. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ,
Chapman JR. 2001. Effect of histological damage on long term kidney transplant
outcome. Transplantation 71: p. 515-523.
27. Nankivell BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RD, Chapman JR. 2003.
The natural history of chronic allograft nephropathy. N Eng J Med 349: p. 2326-2333.
28. A J Matas, R L Simmons, C M Kjellstrand, and J S Najarian. 1977. Pseudorejection:
factors mimicking rejection in renal allograft recipients. Ann Surg. 186(1): p. 51–59.
29. Mackie GC, Davies PF, Challis DR, Middleton IS. 2004. Renal infarction secondary
to a subcapsular haematoma following percutaneous renal biopsy. Australas Radiol.
48(2): p. 207-210.

24

30. Machida J, Kitani K, Inadome A, Wada Y, Kawabata K, Yoshida M, Ueda S. 1996.
Subcapsular hematoma and hypertension following percutaneous needle biopsy of a
transplanted kidney. Int J Urol 3(3): p. 228-230.
31. Ellingsen A, Nyengaard J, Osterby R, Jurgensen K, Peterson S, Marcussen N. 2002.
Measurements of cortical interstitium in biopsies from human kidney grafts: how
representative and how reproducible? Nephrology Dialysis Transplantation 17: p.
788-792.

25

CHAPTER 3- REVIEW OF PROPOSED NONINVASIVE METHODS FOR
DETECTING ACUTE REJECTION
In response to the aforementioned fundamental problems with using serum creatinine as a
marker for AR, many proposed biomedical technologies to detect AR have been explored. Some
require disruption of cellular biology and immunological integrity while others that are
successful in studying the immune system in its confluent form are limited by the need to
analyze byproducts of an up-regulated immune system. These byproducts are often subject to
influence by both endogenous and exogenous factors which makes direct correlation with the
presence of AR difficult. Li and colleagues [1] have proposed using polymerase chain reaction
(PCR)-based methodologies in the measurement of urinary mRNA specific for granzyme B and
perforin, two proteins that are increased in the inflammation/infection process. Limitations of
this proposed AR screening modality are based on the observation that these mRNAs are nonspecific and may be up-regulated in cases of inflammation, infection, as well as T cell mediated
allograft rejection, and thus fail to address the issue of specificity. In addition, PCR technology,
though a more prevalent part of clinical laboratory tests, still requires significant expertise and
labor, making it a less than desirable screening tool. Sarwal and colleagues [2] have proposed
using biopsy samples to identify characteristic gene expressions which are associated with
clinical AR. Though a promising concept, this Genechip© technology still relies on obtaining
invasive biopsy samples which are not without risk and are still subject to sampling error.
Moreover, the patient selection process (who is chosen for biopsy) is dependent on less than
accurate selection criteria (serum creatinine) thus leaving the issues of unwarranted referral and
burden to the health care system unresolved. Even when considering Hildalgo and colleagues [3]
proposed use of RNA microarrays that are carried out from peripheral blood-derived T
lymphocytes, the infrastructure, costs, and labor intensive processing once again disqualify it as a
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practical screening tool. Wishart and colleagues [4] have suggested using metabolomics as an
AR detection modality. This mass spectrometry-based technology focuses on identifying
increased levels of key metabolites that are produced in the setting of AR, mainly
trimethylamine-N-oxide (TMAO) and dimethylamine (DMA). Although it adequately addresses
the specificity question, there are still two major limitations to this screening modality. First, the
clearance of the aforementioned metabolites can be strongly influenced by medications such as,
cyclosporine or tacrolimus that may compete at the level of hepatic transporters (i.e. cytochrome
P450) [5]. This is of concern in the transplant patient population due to the many comorbidities
that require medicinal management. Secondly, many of these patients have impaired liver
function due to previous alcohol use, and/or hepatitis disease, which may alter liver metabolism
and elimination kinetics and drastically affect the sensitivity and specificity of this method.
Finally, the analysis of Metabolomics-derived data requires software which utilizes intricate
numerical methods thus increasing cost and requiring specialized knowledge and/or training [4].
One possible solution to the many limitations of the noninvasive methodologies stated
above is to directly study the principal immune effector cell, the T lymphocyte, in the confluence
of its actions within the intact immunological landscape in a noninvasive manner with a system
that does not require labor-intensive preparation, processing, or analysis. Such a methodology
would thereby avoid byproducts, invasive biopsies, varying patient pharmacokinetics,
unjustifiable costs, and delays in diagnosis. We propose that RS represents such a methodology.
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CHAPTER 4- RAMAN SPECTROSCOPY AS A DIAGNOSTIC TOOL
Chapter 4.1- Historical Background of Raman Spectroscopic Technology
The original concept of quantitative scattered light was proposed by the Austrian
theoretical physicist, Adolf Smekal (1895-1959) in 1923 [1].

However, the phenomenon was

not actually observed until 1928 when young Indian physicist Chandrasekhara Venkata Raman
(1888-1970) along with K S Krishnan (1898-1961) demonstrated that light reflected back from
an object was not merely light reflecting back unchanged (i.e. elastic fraction of scattered light)
[2]. Instead, there was also a fraction of scattered light that reflected back with a different
wavelength (i.e. inelastic fraction of scattered light). By utilizing sunlight passed through a
narrow-band photographic filter to create monochromatic light and a crossed filter to
differentially subtract out this monochromatic light, Raman was able to recreate and observe
what was only theorized by Smekal [2]. In 1930, Sir Raman was awarded the Nobel Prize in
physics for his contributions to the technologic tool that now bears his name. His original
experimental design would be further refined through the years by Placzek, Bethe, Teller, Frisch,
and many other prominent physicists [3].
Modern-day RS has proved invaluable in the fields of material science and chemical
engineering due to its ability to characterize substances based upon their vibrational, rotational
and other low energy modes [4].

The scattered fraction of light is generated when light

interacting with the molecule being studied polarizes electrons surrounding the nuclei. This
polarization reflects a transient or virtual state of the photon. When this interaction leads to
electron distortion alone, the resultant frequency change is small and the scattered light is of the
elastic type often referred to as Rayleigh scattering [5]. As depicted in Figure 7, this light returns
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to the source unchanged. However, if nuclear motion occurs as a result of the light interacting
with the molecule, then measurable energy will be transferred between incident photon and
molecule generating an inelastic fraction of scattered light called Raman scattering [5]. Raman
scattering can be further divided into stokes and anti-stokes scatterings (Figure 7). When the
final ground state of the molecule has more energy than the initial state, the photon emitted will
be at a lower frequency. This is known as Stokes Raman scattering. However, when the final
state has less energy than the initial state, the emitted photon will have higher frequency than the
excitation frequency and is considered anti-Stokes Raman scattering (Figure 7) [5]. The
aforementioned scattering process can be represented by the following expressions [2]:
hvs = hvo ± hvm.

(1)

Here, h is the Planck’s constant, v represents frequency, hvo is the incident photon energy, hvs is
the scattered photon energy, and hvm is the difference between the lowest and the first excited
energy levels. In studies involving RS, Raman shift is usually the metric which is given by the
equation:
∆ν = v0 − ν s

(2)

However, this is most often expressed in wavenumber (cm-1):

ν =c / λ

(3)

Here c represents the speed of light. Combining expressions 1-3 yields the Raman shift given as:

 1
1
∆ν = v0 ± ν s = c  − 
 λo λ s 

(4)
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Both stokes and anti-stokes are forms of inelastic scattering and despite the fact that the
most dominant form of scattered light is of the elastic fraction, the inelastic fraction, which
comprises only one out of every 106-108 photons, yields the wealth of information concerning
the molecules being studied [5]. This information can be translated into a spectral signature
unique to the particular material [6].

Figure 7. Energy levels and light scatterings involved in Raman spectroscopy [5].
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As the technology regarding RS has improved and evolved, the analyzing power and
breadth of substances analyzed has increased while the system’s profile and physical footprint
have decreased which has been demonstrated by a wave of portable handheld RS devices that
have entered the market. Representative RS schematic, traditional, and portable device images
are depicted in Figures 8, 9, and 10, respectively.

Figure 8. General schematic for Raman spectroscopic analyzer. 1-laser; 2-detector; 3-charge-coupled
device; 4-diffraction grating; 5-slit; 6-Raman scattered light; 7-Rayleigh filters;
8-scattered light; 9-sample with lymphocyte culture.

32

Figure 9. Image of Renishaw Raman Spectroscopic analyzer with open (left) and closed (right) microscope hood.

Figure 10. Portable Raman spectroscopic devices. (Left) MiniRam, (center)
MiniRam II (B&W Tec), and (right) InPhotote (InPhotonics)
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Chapter 4.2- Biologic Applications of Raman Spectroscopy

The RS quantitative analysis of biologic materials, and more specifically, the individual
components of these materials that could represent effective biomarkers, is complicated by
several factors that are indissoluble from the biologic nature of these materials. First, nearly all
biologic/biochemical material from pure water to living cells emit fluorescence at certain
wavelengths. This fluorescence, which is usually at much greater intensity than peaks of interest,
makes component analysis difficult. In general, incident photon wavelengths that yield higher
resolution also demonstrate a greater tendency toward fluorescence. This spectral interference
can be partially avoided by choosing the proper bathing media and by utilizing multi-spectral
analysis and wavelengths that cause less fluorescence emission. In certain circumstances, peaks
of interest may be located in regions of the spectrum that have negligible fluorescence, but this
must be assessed on a case-by-case basis. Second, spectra of proteins and macromolecules are
the sum total of the amino acid (AA) and subunit components. These elements exist on a
continuum with extensive overlap of AA residues which results in, analytically, an averaged
rather than discrete contribution. This challenge can be partially addressed by computer models
[5] that can use spectral information derived from purified protein/subunit samples analyzed in
isolation to deconstruct Raman peaks. However, this approach is limited and does not take into
account the contribution of inter-protein interaction and its affect on the tertiary structure of
proteins. To expand this example further, one can consider the living cell, which represents a
biologic symphony containing countless carbohydrates, lipids, nuclear material, and proteins that
scatter light at different intensities. The presence of these variable intensities makes it extremely
difficult to isolate the contribution of one component and truly gauge its significance to the
overall structure of the material being studied. This latter notion of structural significance can be
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illustrated more simplistically if one were to consider a bottle made of a polymer which contains
sulfur [5]. Polymers are weak Raman scatterers while sulfur is a strong scatterer. If the bottle
was analyzed using RS, the spectrum would be dominated by sulfur peaks. However, the
abundance of these peaks does not imply that the polymer is made predominately of sulfur
molecules. The principles of this example can be extracted and applied to the study of living
cells. If the structural significance of only two organic molecules contained in a matrix, the
bottle, can be misinterpreted, then one can imagine the potential pitfalls that a cell, which has
myriad of molecules in a multifaceted matrix, can present. Care should be taken when drawing
conclusions about the global structure of a biologic or biochemical sample. Lastly, the living cell
is susceptibility to heat, fungal/bacterial contamination, and damage due to excessive handling.
These perturbations can significantly change the spectral signatures and make reproducibility of
results problematic. For the most part, these issues can be addressed through proper experimental
design and although quantitative analysis of the components in a biological system has posed
unique challenges, the proper experimental design, ancillary resources (i.e. peak assignment
databases for purified sample and analyzing software), and careful interpretation, has allowed RS
to be developed into a valuable tool for the identification of biomarkers important to disease
conditions. This can be illustrated by the success of RS in the areas of cellular biology, pathogen
detection, and oncological identification [7-13]. Germaine to these studies has been the
observation that RS is effective at quantifying differences and characteristics of individualized
cells and their components. These Raman shifts can imply specific information concerning the
cellular composition, cell surface biologic topography, and underlying biomolecular processes.
The breadth of potential analysis carried out by RS can be further appreciated when considering
that Takai and colleagues [14] were able to demonstrate the use of RS in characterizing cytotoxic
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granules within cells while Notingher and others [15] demonstrated its utility in identifying
specific peaks, 788 cm-1 and 1000.43 cm-1, which reliably differentiated viable from nonviable
whole cells. These observations were made possible by correlating the molecular-based
signatures with the biological processes of DNA/RNA, carbohydrates, lipids, and protein
alteration which occur on a cellular level [16, 17].
For this specific investigation of AR detection, the high resolution of RS was utilized to
quantify the aforementioned cell surface receptor differences (see Section 2.1 The Immunologic
Basis of Renal Allograft Rejection) between activated and non-activated T lymphocytes. In

addition to its high resolution, RS offers many novel attributes that make it a potentially effective
diagnostic tool. One of these attributes is that the system can be completely automated and
contained in a device small enough to fit on the table-top in the clinical setting. This eliminates
the need for specially-trained staff or large infrastructures/laboratories for processing of samples,
two requirements that hampered previously-proposed noninvasive methods. In addition, RS
affords rapid analysis (measurements can be completed in less than 10 minutes) and requires
minute amounts of sample (blood or urine) to produce specific signatures. Unlike infrared
spectroscopy, RS does not require the operator to match the frequency of the incident photon to
that of the vibration of the particular molecule in order to promote that molecule to a vibrational
excitation state and unlike flow cytometry, RS does not require expensive antibodies to carry out
analysis. The implication of these observations is that there is less processing and pretest
manipulation of samples using a RS system [5]. All of these attributes suggest that this
technologic platform can be developed into a highly accurate, noninvasive diagnostic tool for
AR.
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CHAPTER 5- RAMAN SPECTROSCOPIC DIFFERENTIATION OF ACTIVATED
VERSUS NON-ACTIVATED T LYMPHOCYTES: AN IN VITRO STUDY OF AN
ACUTE ALLOGRAFT REJECTION MODEL [1]
Chapter 5.1- Introduction

As mentioned previously, we hypothesize that the differentiation of activated and nonactivated (resting and inactivated) T lymphocytes can be accomplished by using RS analysis of
cell surface receptors. The goal of the study presented in this chapter was to investigate initial
spectral signature differences between activated (alloreactive) and non-activated T lymphocytes
and to assess the effectiveness of an in vitro cellular model that will allow the necessary analysis
on a RS platform.
Chapter 5.2- Materials and Methods
5.2.1- Cellular Preparation

Following approval from the Wayne State University Human Investigation Committee
(HIC; Appendix F), mononuclear cells were obtained using freshly drawn (within 3 hours of
experimentation) sodium-heparinized venous blood collected from healthy individuals and
separated according to density via high molecular weight sucrose polymer (ficoll) as described
by Boyum [2]. The resultant cells were washed three times using Hank’s balanced salt solution
(HBSS, Invitrogen, Carlsbad, CA) and suspended in McCoy’s solution/5% fetal calf serum
(Biofluids, Rockville, MD) prior to T lymphocyte isolation. B lymphocytes were subsequently
removed by negative selection using FluoroBeads-B immunomagnetic beads and magnetic sorter
(One Lambda, Canoga Park, CA). This process was repeated twice with chilled phosphate
buffered saline (PBS; Invitrogen, Carlsbad, CA) washings used to suspend cells between
magnetic separations. Cell viability was >98% as checked by vital dye exclusion. T lymphocyte
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enriched samples were suspended in complete medium and aliquoted for subsequent
experimentation.
5.2.2- Peripheral Blood T Lymphocyte Samples

Three distinct T lymphocyte sample groups were created for the study, consisting of
activated, inactivated, and resting T lymphocytes. The activated T lymphocyte samples were the
product of a two-way mixed lymphocyte culture (MLC) as described by Dupont and colleagues
[3].

The inactivated group was created using T lymphocyte/stimulator samples from two

unrelated individuals that were pretreated for 20 minutes with Mitomycin C (0.025 mg of
Mitomycin C (0.5 mg/ml) to each 1 ml of cell suspension) at 37°C and washed twice using
HBSS prior to start of MLCs. Efficacy of Mitomycin C was verified using double inactivation
control cultures which were run in parallel. Finally, the resting T lymphocyte sample group was
defined as T lymphocytes obtained by methods described previously, which were neither
stimulated via MLC nor inhibited by Mitomycin C treatment. Following MLC but prior to RS
analysis, B cells were removed by negative selection using FluoroBeads-B immunomagnetic
beads and magnetic sorter (One Lambda, Canoga Park, CA) while monocytes/macrophages were
removed via steel wool columns to ensure that these signatures were not obtained erroneously.
All cultures were incubated at 37°C in 5% CO2 in parallel over a 7-day period with RS testing,
antibody analysis, and viability assays carried out daily.
5.2.3- Independent Verification of Activation/Inactivation via Antibody Staining

Activation and inactivation of representative aliquots were verified using FastImmune
anti-Hu-Il-2 FITC/CD69 PE/CD4 Per CP- Cy5.5/CD3 APC (Becton Dickinson, San Jose, CA),
with 94% of MLC (activated) and 100% of Mitomycin C-treated (inactivated) T lymphocytes
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staining positive and negative, respectively, using protocols described elsewhere [4].

In

addition, there was no detected activation due solely to physical handling of lymphocytes.
Stained cells were viewed using a Nikon Eclipse TE 2000-U inverted microscope with images
being captured and processed using Metavue 6.2r5 software (Downingtown, PA).
5.2.4- Raman Spectroscopic Analysis

Prior to analysis, all samples were washed with PBS (Invitrogen, Carlsbad, CA). Cells
were allowed to settle within the analysis reservoir placed on a leveled microscope stage. Only
rounded, non-adhered, isolated and individualized T lymphocytes were selected for study. Each
sample was analyzed using identical protocol and spectroscopic parameters. Using an enhanced
video imaging system, T cells were aligned in the laser target area so that the focus point was
centered on the lymphocyte. Images were captured before and after each measurement with no
noted cell shifting or destruction observed. Wire 2 software (Renishaw plc, Old Town, United
Kingdom) was utilized in conjunction with the Raman system for quantitative measurement.
Raman spectroscopic measurements were conducted using a Renishaw InVia 2000 microscopespectrometer with a Leica 63X water immersion objective (NA= 1.20). Due to the complexity of
biological structures which can embody numerous vibrational modes, two different excitation
wavelengths were used in this study. T lymphocytes were analyzed using both 785 nm (red)
diode and 514.5 nm (green) Ar+ excitation wavelengths. Laser power was set at 50% (8-12 mW)
for a 2-4 µm laser spot size. Spectra were collected in the backscattering geometry with a 10
second integration time over a range of 500 to 1700 cm-1. The theoretical spectral resolution was
~ 4 cm-1. A schematic of the Raman spectroscopic system is depicted in Figure 8.
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5.2.5- Statistical Analysis

Prior to statistical analysis, all data was checked for various types of noise. There was no
significant fluorescence observed for the 785 nm wavelength excitation. However, with the
514.5 nm excitation, Raman spectral data showed fluorescence uniformly increasing over the
entire range of Raman shift. This fluorescence was subtracted out using a modified cubic-spline
algorithm that required no a priori knowledge of the spectra. In addition, a median filter was
applied to raw data to eliminate any cosmic ray or spikes in the data. The Raman spectra from all
data contained 1184 data points. To determine the independent variations in the intensity which
basically represents different pathological states in the sample, we used principal component
analysis (PCA) to reduce dimensionality in the data. We found that seven eigenvectors were able
to capture more than 97% of total variance in the data. Student’s t-test was utilized to further
quantify differences in peak ratios. The data were further analyzed for the presence of various
independent groups using discriminant function analysis (DFA) with the aforementioned
eigenvectors as input variables. Graphical and quantitative analysis of data was accomplished
using SPSS version 15 software (Statistical Software, Chicago, IL).
Chapter 5.3- Results
5.3.1- Raman Spectroscopic Results - Green (514.5 nm) Laser

A total of 23 activated, 12 inactivated, and 20 resting T lymphocytes were examined. A
representative mean Raman spectrum of resting T lymphocytes is depicted in Figure 11 with
proposed peak assignments for 1182 cm-1 and 1195 cm-1 positions shown in Appendix B. There
was no observed cellular disruption during measurements, and after comparison of activated and
non-activated (resting and inactivated) spectra from 500-1700 cm-1, qualitative differences were
seen at the 1182 cm-1 and 1195 cm-1 positions.
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Representative activated and inactivated T lymphocyte spectra are depicted in Figures
12A and 12B, respectively. Ratios of the 1182 cm-1 and 1195 cm-1 peaks were determined by

comparison of amplitudes with respect to a designated baseline depicted by a dashed line in the
figures. The average peak ratios for the 1182 cm-1 and 1195 cm-1 positions for the activated,
inactivated, and resting T lymphocyte groups were 0.98 ± 0.04, 1.13 ± 0.10, and 1.10 ± 0.05,
respectively. Significant differences in peak ratios existed between activated and resting as well
as between activated and inactivated T lymphocyte groups (p = 0.001 and p = 0.0001,
respectively). There was a trend observed in the differences between inactivated and resting T
lymphocytes (p = 0.07).
A summary of all RS data collected with 514.5 nm excitation for activated, inactivated,
and resting T lymphocytes is shown in Figure 13. Based upon the distribution of raw data, 3
distinct sectors were assigned for grouping purposes: Sector I, inactivated T cells; Sector II,
activated T cells; Sector III, resting T cells. 95.7% of activated T lymphocytes clustered in Sector
II, with the remaining 4.3% clustering in Sector I. One hundred percent of inactivated T
lymphocyte samples clustered in Sector I, while 60% of the resting T lymphocytes were found in
Sector III, and 40% in Sector I. This data supports a 96% Sensitivity (defined here as the ability
to detect T cell activation) and a 100% Specificity (defined here as the ability to detect nonactivated T cells or rule out T cell activation).
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Figure 11. Raman spectroscopic analysis of T lymphocytes using 514.5 nm laser over a range of 500-1700 cm-1.
Representative T cell (inset a) demonstrating cellular integrity following analysis.
(*) Indicates area of focus containing the 1182 and 1195 cm-1 peaks.
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Figure 12. (A) Raman spectroscopic analysis of 1182 cm-1 (*) and 1195 cm-1 (^) peaks for activated T lymphocytes
at the 514.5 nm wavelength. Inset a shows independent verification of activation via anti-IL-2/CD69/CD4/CD3
antibody staining. (B) Spectroscopic analysis of inactivated T lymphocyte, with inset b showing non-activation.
Ratios determined by amplitude with respect to designated baseline (dashed line).

Figure 13. Discriminant function analysis of T lymphocytes at 514.5 nm wavelength plotted without (A) and with
(B) assigned sectors. Sectors I, II, and III correspond to inactivated, activated, and resting samples, respectively.
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5.3.2- Raman Spectroscopic Results - Red (785 nm) Laser

A total of 28 activated, 16 inactivated, and 15 resting T lymphocytes were examined. A
representative mean Raman spectrum of resting T lymphocytes is depicted in Figure 14. There
was no observed cellular disruption following laser exposure.
The average peak ratios for the 1182 cm-1 and 1195 cm-1 positions for the activated,
inactivated, and resting T lymphocyte groups were 0.93 ± 0.05, 1.15 ± 0.10, and 1.09 ± 0.09,
respectively. Representative activated and inactivated T lymphocyte spectra are depicted in
Figures 15A and 15B, respectively. Significant differences in peak ratios existed between

activated and inactivated as well as between activated and resting T lymphocytes (p = 0.001 and
p = 0.006, respectively). In contrast, there was only a trend seen in differences between
inactivated and resting T lymphocytes (p = 0.08). Figure 16 demonstrates the DFA plot for
activated, resting, and inactivated T lymphocyte Raman spectral data collected using the 785 nm
wavelength. 89.3% of the activated T lymphocytes grouped into Sector II, with 3.6% falling into
Sector I and 7.1% clustering into Sector III. 93.8% of the inactivated T lymphocytes were found
in Sector I, while 6.2% marginalized into Sector III. 86.6% of the resting T lymphocytes were
found in Sector III with 13.4% clustering into Sector I. This data supports an 89.3% Sensitivity
and a 93.8% Specificity.
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Figure 14. Raman spectroscopic analysis of T lymphocytes using 785 nm laser with range of 500-1700
cm-1. Representative T cell (Inset a) demonstrating cellular integrity following analysis.
(*) Indicates area of focus containing the 1182 and 1195 cm-1 peaks.
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Figure 15. (A) Raman spectroscopic analysis of 1182 cm-1 (*) and 1195 cm-1 (^) peaks for activated T lymphocytes
for the 785 nm wavelength. Inset a shows independent verification of activation via anti-IL-2/CD69/CD4/CD3
antibody staining. (B) Spectroscopic analysis of inactivated T lymphocyte with inset b demonstrating non-activation.
Ratios determined by amplitude with respect to designated baseline (dashed line).

Figure 16. Discriminant function analysis of T lymphocytes at 785nm wavelength plotted without (A) and with (B)
assigned sectors. Sectors I, II, and III correspond to inactivated, activated, and resting samples, respectively.
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Chapter 5.4- Discussion

The process of T lymphocyte activation spans from initiation of the genetic apparatus via
immunospecific transcription factors to the up-regulation of glycoproteins and lipid turnover on
the T lymphocyte surface. In general, Raman peak assignments can be categorized as nucleic
acid, carbohydrate, lipid, or protein in nature. Indeed, this process of activation encompasses all
peak assignment categories and importantly, can be quantified by our RS system.
The purpose of this study was to utilize RS to establish spectral differences between
activated and non-activated T lymphocytes. Initial qualitative comparison of activated and nonactivated T lymphocytes yielded notable foci at five distinct positions in the Raman spectrum:
628 cm-1, 788 cm-1; 1000.43 cm-1; 1182 cm-1; and 1195 cm-1. Peaks at 628 cm-1, 788 cm-1, and
1000.43 cm-1 have been previously identified and described as markers for cellular viability [5].
However, a novel and distinct spectral difference in peak positions was observed at 1182 cm-1
and 1195 cm-1. These differences, and more importantly their ratio to one another, have not been
previously described.
The in vivo immunologic landscape concerning the activation of T lymphocytes exists on
a continuum, with the breadth of the spectrum ranging from anergy to full activation [6]. The
observation that a small subset of activated T lymphocytes in both the 514.5 nm and 785 nm
cohorts were found in Sectors I and III, or the inactivated and resting T lymphocyte sectors,
respectively, can be explained by the concept of anergy or the inability to up-regulate receptors
of activation due to the absence of the co-stimulatory feedback, signal 2 (see Section 2.1
Immunologic Overview and Figure 2) [6]. In vivo, this process ideally prevents a T lymphocyte

from reacting and clonally expanding in response to a self antigen without confirmation. To
further address this issue and verify this phenomenon, we conducted a study to circumvent
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anergy through a method of non-specific activation that is independent of MHC restriction (see
Chapter 6). No inactivated T lymphocytes were found in Sector II. This important observation

verifies the notion that although we would expect a small percentage of alloreactive T
lymphocytes to fail to activate due to anergy, we would not expect a Mitomycin C-treated T
lymphocyte to activate and thus falsely group with activated samples in Sector II. This also
suggests that an eventual high specificity of RS can be achieved. This notion was tested and is
addressed in Chapter 6.
Although the difference in average peak ratios between resting and inactivated T
lymphocyte groups of both green and red lasers did not quite reach statistical significance, the
trend toward difference depicted in the DFA plots were graphically apparent, allowing for
discrimination. The exchangeability found between Sectors I and III that did not exist for Sector
II suggests that there is a threshold of activation required to populate the T lymphocyte surface
with a density of receptors necessary to create a distinct activation signature.
Based upon Raman spectra from excitation wavelengths 514.5 nm and 785 nm, average
peak ratios, and DFA plots, there was a significant difference observed between the activated T
lymphocyte group and the non-activated (resting and inactivated) T lymphocyte groups. When
considering both wavelengths, the green laser demonstrated a higher resolution and tighter
association of T lymphocytes to their designated sector, with 96% of activated T lymphocytes
aggregating into Sector II (sensitivity) and 100% of inactivated T lymphocyte samples
aggregating into Sector I (specificity). We utilized this observation in the planning of subsequent
experiments in which we employed the 514.5 nm (green) laser exclusively.
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CHAPTER 6- DIFFERENTIATION OF ALLOREACTIVE VERSUS CD3/CD28
STIMULATED T LYMPHOCYTES USING RAMAN SPECTROSCOPY: A GREATER
SPECIFICITY FOR NONINVASIVE ACUTE RENAL ALLOGRAFT REJECTION
DETECTION [1]
Chapter 6.1- Introduction

In the preceding chapter, (Ch. 5) the notion of sensitivity (the ability to distinguish
activated from non-activated T lymphocytes) was explored. Despite the establishment of RS as a
methodology to identify T lymphocyte activation, the specificity of this system, defined here as
the ability to distinguish signatures of two sets of T lymphocytes that are activated by different
stimuli, still required examination. This study focuses on spectral signature differences of
alloantigen-activated and CD3/CD28-activated T lymphocytes. We hypothesize that the RS
signatures of T cells activated via these two methodologies will differ significantly.
Chapter 6.2- Materials and Methods
6.2.1- Alloantigen-activated T Lymphocyte Preparation

Prior approval for the study was obtained from the Wayne State University HIC.
Mononuclear cells were obtained from healthy volunteers using protocol described previously
(see section 5.2.2).
Three distinct T cell sample groups were created for the alloantigen-activated T cells: 1.
activated; 2. inactivated; and 3. resting T lymphocytes. The activated T lymphocyte samples
were created via a two-way MLC as described previously (see section 5.2.2). T cell activation
was confirmed by CD69 directed flow cytometry (Appendix C) [2, 3]. The inactivated group
was created by utilizing T lymphocyte/stimulator samples from two non-related individuals
which were pretreated with Mitomycin C as previously described (see section 5.2.2). Finally, the
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resting T lymphocyte group consisted of lymphocytes that were neither stimulated via MLC nor
inhibited by Mitomycin C treatment. These cells were the product of CD69 negative sorting via
flow cytometry [2, 3]. All cultures were incubated at 37 degrees Celsius in 5% CO2 in parallel
over a 7-day period, with RS, antibody, and viability analysis carried out daily.
6.2.2- Non-specific Antigen Model of Activation

T lymphocytes were isolated directly from peripheral blood and urine using a Dynal T
cell negative isolation kit (Invitrogen, Canoga Park, CA). In order to model a nonspecific
process of activation, a CD3/CD28-coated Dynal bead system (Invitrogen, Canoga Park, CA)
was utilized to cross-link cell membrane molecules. This consisted of T lymphocytes incubated
with beads (bead volume titrated to correspond to 3 beads for every T cell at a concentration of 1
x 107 cells per volume) in complete media containing recombinant interleukin 2 (50U/ml). The
CD3/CD28 beads were removed from T lymphocytes via high efficiency magnetic sorter prior to
Raman analysis.
6.2.3- Independent Verification of Activation/Inactivation

Independent of RS analysis, the activation status of all samples was verified by antibody
staining and flow cytometry (Appendix C). For the alloreactive and CD3/CD28 stimulated
samples, activation status was assessed using a monoclonal antibody, CD69 (FastImmune,
Becton Dickinson, San Jose, CA), as described elsewhere [4]. Stained cells were viewed using a
Nikon Eclipse TE 2000-U inverted microscope, with images captured and processed with
Metavue 6.2r5 software (Downingtown, PA).
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6.2.4- Raman Spectroscopic Analysis

Lymphocyte selection, Raman measurement parameters, and cellular integrity
verification was carried out as previously described (see section 5.2.4). To provide for
reference/control spectral peaks, both pure CD3/CD28 beads and T lymphocytes that were not
subjected to magnetic sorter (T cells still bound with beads), were analyzed. Wire 2 software
(Renishaw plc, Old Town, United Kingdom) was utilized in conjunction with the RS system for
quantitative measurement.
RS measurements were conducted using a Renishaw InVia 2000 microscopespectrometer with a Leica 63 X water immersion objective (NA = 1.20). T lymphocytes were
analyzed using the 514.5 nm (green) Ar+ excitation wavelength. Laser power was set at 50% (812 mW) for a 2-4 µm laser spot size. Spectra were collected in the backscattering geometry with
a 10 second integration time over a range of 600 to 1700 cm-1 with a spectral resolution of
4 cm-1.
6.2.5- Statistical Analysis

Prior to statistical analysis, all data were checked for various types of noise. Spectral data
demonstrated uniformly increasing fluorescence over the entire range of Raman shift. This was
subtracted out using a modified cubic-spline algorithm requiring no a priori knowledge of the
spectra. In addition, a median filter was applied to the raw data which eliminated cosmic ray and
spikes. PCA was used to reduce dimensionality in the data. Chi square or Student’s T test was
utilized as appropriate to further quantify differences in peak ratios and peak magnitudes with
additional quantitative differences determined by DFA. Graphical and quantitative analysis of
data were accomplished using SPSS version 15 software (Statistical Software, Chicago, IL).

55

Chapter 6.3- Results
6.3.1- CD3/CD28-activated versus Inactivated T Lymphocytes

A total of 75 CD3/CD28-activated and 75 inactivated T cells were analyzed using the
514.5 nm excitation wavelength. Systematic review of samples revealed no cellular disruption
following laser exposure. Qualitative comparisons of activated and inactivated spectra
demonstrated differences at 903 cm-1, 1031 cm-1, 1069 cm-1, 1093 cm-1, 1155 cm-1, 1326 cm-1,
and 1449 cm-1 peak positions (Figure 17). Quantitative analysis of these shifts demonstrated
differences in peak magnitudes at all positions except for 628cm-1, 788 cm-1, and 1002 cm-1
(Table I, Figure 18A-E), which have been shown in previous studies to correlate with cellular

viability [5]. Moreover, the CD3/CD28-activated and inactivated groups showed significant
differences in peak ratios at the 1182:1195 cm-1 position (Table I, Figure 19).
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Figure 17. Superimposed mean Raman spectra from inactivated (red) and CD3/CD28-activated T lymphocytes
annotated with (*) foci of significant differences and (^) markers of cellular viability [5].
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Figure 18. Raman spectra of inactivated (red) and CD3/CD28-activated (blue) T lymphocytes demonstrating
differences in peak magnitudes (insets A, D, and E) and comparable peaks at viability markers (Insets B and C).
Annotations within insets: Inset A- (*) 903 cm-1; Inset B- (^) 788 cm-1; Inset C- (*) 1002 cm-1;
Inset D- (*) 1031 cm-1, (^) 1069 cm-1, (‡) 1093 cm-1, (•) 1155 cm-1; Inset E- (*) 1326 cm-1, (^) 1449 cm-1.
Note: These focused spectral regions are from T lymphocytes represented in Figure 17.
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Figure 19. Raman spectra of inactivated (red) and CD3/CD28-activated T lymphocytes demonstrating differences in
(*) 1182 cm-1 and (^) 1195 cm-1 peaks.

6.3.2- CD3/CD28-activated versus Alloantigen-activated T Lymphocytes

A total of 46 CD3/CD28-activated and 40 alloantigen-activated T cells were analyzed
with summary comparison spectra shown in Figure 20. When comparing these groups, they
differed significantly at the 903 cm-1, 1031 cm-1, 1093 cm-1, 1155 cm-1, 1326 cm-1, and 1449 cm-1
positions. However, there was no difference when analyzing the peak ratio at the 1182:1195 cm-1
position (Figure 20, Table I). DFA of the Raman spectral data for CD3/CD28-activated and
alloantigen-activated T cell groups is summarized in Figure 21. There was 100% accuracy when
using the activation signature to separate these groups.
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Figure 20. Superimposed mean Raman spectra from CD3/CD28-activated (red) and alloreactive T
lymphocytes annotated with (*) foci of significant differences and (^) markers of cellular viability [5].
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Figure 21. Discriminate function analysis of alloreactive versus CD3/CD28-activated T lymphocytes.
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Table I. Comparative summary of relevant Raman shifts of CD3/CD28-activated, inactivated,
alloreactive, and resting T lymphocytes. (See Abbreviation key below Table)
PA

PM of NSA (75) PM of NSA (75) PM of NSA (46) PM of Allo (40) PM of Allo (40) PM of Rest (75)
vs. Inact (75);%∆; vs. Rest (75); %∆; vs. Allo (40); %∆; vs. Inact (75); vs. Rest (75); %∆; vs. Inact (75);
(cm )
P Value
P Value
P Value
%∆; P Value
P Value
%∆; P Value
-1

628

1663.24 vs.
1684.01;

1663.24 vs.
1652.33;

1663.24 vs.
1602.52;

1602.52 vs.
1684.01;

1602.52 vs.
1652.33;

1652.33 vs.
1684.01;

NA; 0.7

NA; 0.9

NA; 0.3

NA; 0.12

NA; 0.6

NA; 0.89

805.86 vs. 818.95; 805.86 vs. 807.50; 805.86 vs. 809.2; 808.1 vs. 818.95; 808.12 vs. 807.50; 807.50 vs. 818.95;
788
NA; 0.91

NA; 0.72

NA; 0.62

NA; 0.75

NA; 0.9

NA; 0.88

736.7 vs. 828.92;

736.7 vs. 819.62;

↑ 12.5%; 0.004

↑ 11%; 0.007

↑ 10%; 0.01

NA; 0.4

NA; 0.09

NA; 0.09

5279.08 vs.
5438.8;

5279.08 vs.
5520.1;

5279.08 vs.
5490.2;

5490.2 vs.
5438.8;

5490.24 vs.
5520.1;

5520.1 vs.
5438.8;

NA; 0.82

NA; 0.8

NA; 0.78

NA; 0.91

NA; 0.8

NA; 0.76

1390.8 vs.
1837.18;

1390.8 vs.
1815.92;

1390.8 vs.
1805.56;

1805.5 vs.
1837.1;

1805.5 vs.
1815.92;

1815.92 vs.
1837.1;

↑ 32%; 0.002

↑ 31%; 0.005

↑ 29.8%; 0.003

NA; 0.62

NA; 0.09

NA; 0.4

736.7 vs. 814.89; 814.89 vs. 828.9; 814.89 vs. 819.62; 819.62 vs. 828.92;

903

1002

1031
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Table I (cont). Comparative summary of relevant Raman shifts of CD3/CD28-activated,
inactivated, alloreactive, and resting T lymphocytes.
PA

PM of NSA (75) PM of NSA (75) PM of NSA (46) PM of Allo (40) PM of Allo (40) PM of Rest (75)
vs. Inact(75); vs. Rest (75); %∆; vs. Allo (40);
vs. Inact (75);
vs. Rest (75);
vs. Inact (75);
(cm )
%∆; P Value
P Value
%∆; P Value
%∆; P Value
%∆; P Value
%∆; P Value
-1

1069

1093

1155

1182:
1195*

1326

1449

980.32 vs.
1024.0;

980.32 vs.
1012.8;

980.32 vs.
1021.7;

1021.7 vs.
1024.0;

1021.73 vs.
1012.8;

1012.83 vs.
1024.0;

↑ 4.3%; 0.02

↑ 3.3%; 0.05

NA; 0.4

NA; 0.1

NA; 0.1

NA; 0.65

947.52 vs.
1245.08;

947.52 vs.
1199.85;

947.52 vs.
1145.08;

1145.0 vs.
1245.0;

1145.08 vs.
1199.8;

1199.85 vs.
1245.0;

↑ 32%; 0.006

↑ 27%; 0.004

↑ 31%; 0.04

NA; 0.09

NA; 0.08

NA; 0.09

1463.5 vs.
1914.44;

1463.5 vs.
1938.60;

1463.5 vs.
1924.44;

1924.4 vs.
1914.4;

1924.4 vs.
1938.60;

1938.60 vs.
1914.4;

↑ 31%; 0.005

↑ 32%; 0.009

↑ 31%; 0.03

NA; 0.8

NA; 0.3

NA; 0.1

Ratio: 0.91 vs.
1.2;

Ratio: 0.91 vs.
1.05

Ratio: 0.97 vs.
0.86;

Ratio: 0.86 vs.
1.2;

Ratio: 0.86 vs.
1.05;

Ratio: 1.05 vs.
1.2;

p = 0.006

p = 0.009

p = 0.8

p = 0.007

p = 0.002

p = 0.09

1301.2 vs.
1600.26;

1301.20 vs.
1572.34;

1301.2 vs.
1608.3;

1608.3 vs.
1600.2;

1608.3 vs.
1572.34;

1572.34 vs.
1600.2;

↑ 23%; 0.03

↑ 21%; 0.02

↑ 22.9%; 0.04

NA; 0.21

NA; 0.12

NA; 0.77

1542.33 vs.
1834.9;

1542.33 vs.
1833.02;

1542.3 vs.
1832.92;

1832.9 vs.
1834.9;

1832.92 vs.
1833.0;

1833.0 vs.
1834.94;

↑ 19 %; 0.001

↑ 18.9; 0.002

↑ 19%; 0.001

NA; 0.08

NA; 0.09

NA; 0.08

Data for Table I derived from averaged peak values of CD3/CD28, Inactivated, Alloreactive,
and resting T cell samples at specified peak assignment. Values noted in ( ) correspond to
number of T cells evaluated in each comparison. Abbreviations: PA- peak assignment; NSAnonspecific antigen (CD3/CD28); Inact- inactivated T cells; Rest- resting T cells; Alloalloreactive T cells; PM- peak magnitude; %∆ - percent change in peak magnitude; NA- peak
magnitude change not significant; * Data corresponds to ratio of 1182 to 1195 peaks.
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Chapter 6.4- Discussion

Raman shifts occurring at 903 cm-1, 1031 cm-1, 1093 cm-1, 1155 cm-1, 1326 cm-1, and
1449 cm-1 were observed in the CD3/CD28-activated but not in the alloantigen-activated T cell
samples. These foci of peak differences likely represent a specific conformational change in cell
surface molecules reflecting a response to the particular CD3/CD28 (non-MHC restricted)
stimulus. The greater number of foci of peak differences is related to the non-specific binding of
the beads to the TCR which results in maximum stimulation free of anergy. When cross
referencing these foci with established peak assignment data, they represent changes in nucleic
acids (903 cm-1, 1093 cm-1, and 1449 cm-1), amino acids (1031 cm-1, and 1155 cm-1), or both
(1326 cm-1)- changes which are consistent with molecular processes responsible for the
transcription, translation, and expression of cell surface receptors [20-23] (Appendix B). When
further analyzing these peak differences that were unique to the CD3/CD28-activated T cells,
there was a reduction in peak magnitudes observed in all six of the aforementioned peak
positions. This is most likely represents a reshuffling rather than an absolute down-regulation of
cell surface biomolecular material resulting from conformational changes in receptors, a concept
that will be further explored in Chapter 8.
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CHAPTER 7- BIOMOLECULAR MODELING OF T LYMPHOCYTE ACTIVATION
USING RAMAN SPECTROSCOPY
Chapter 7.1- Introduction

Based on data presented in chapters 5 and 6, which dealt with sensitivity and specificity,
respectively, RS can detect key signature differences between activated and non-activated T
lymphocytes and T lymphocytes that have been activated through different processes. However,
one of the challenges of using RS in the larger biological narrative is linking spectral changes
with biological processes that are known to be occurring and that have been verified through
other independent methodologies. One of these independent methodologies involves using
monoclonal antibodies (mAbs) to analyze the kinetics of cell surface receptor expression. This
concept of kinetics suggests that T lymphocyte activation is defined not only by the characteristic
up-regulation and conformational changes in specific cell surface receptors, but activation is also
dependent on the differential timing of receptor expression.
There are certain specific receptors that are of interest when quantifying T cell activation.
CD69 is a transient activation marker that is expressed as early as 2 hours after activation and is
subsequently down-regulated by 55 hours post-activation [1-4]. Unlike CD69, receptors CD25
and CD71, and the Human Leukocyte Antigen DR (HLA DR) receptor follow a delayed
expression pattern, appearing at 13, 25, and 48 hours following activation, respectively. These
receptors remain at high levels throughout the activation/clonal expansion process. A summary
of receptor expression kinetics is depicted in Figure 22. CD69 is a type II transmembrane
homodimeric glycoprotein that is 22.5 kD in size [5]. CD25 is a 55 kD type I transmembrane
glycoprotein also known as the low affinity IL-2 receptor α chain [6]. CD71, also known as the
human transferrin receptor 1, is a homodimeric type II membrane glycoprotein responsible for
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cellular iron uptake via receptor-mediated endocytosis while HLA DR is a heterodimer which
serves as a ligand for the TCR [7]. The α and β subunits of the HLA DR receptor have two
extracellular domains, a membrane spanning domain, and a cytoplasmic tail. HLA DR is central
to the donor-recipient crossmatching process that minimizes the likelihood of organ rejection [8].
The study outlined in this chapter will focus on the kinetics of CD69, CD25, and CD71.
The goal of this study was to set up a parallel investigation of T lymphocyte activation
using both differential mAb staining and RS. We hypothesized that during the course of
activation, changes in the specific receptors expressed on the cell surface with subsequent
changes in mAb staining patterns would be significant. We further hypothesize that by analyzing
unstained representative lymphocytes at the same time points as the mAb staining, we will be
able to correlate the biomolecular process of up-regulating a cell surface receptor in response to a
stimulus with Raman shifts detected by RS.
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Figure 22. Kinetics of antigen expression [9].

Chapter 7.2- Materials and Methods
7.2.1 Cell Preparation and Mitogen Induction

Prior approval for the study was obtained from the Wayne State University HIC. Sodiumheparinized venous blood was collected from healthy participants and incubated with 40 µL of a
1:1 mixture of Concanavalin A (Canavalia ensiformios agarose; Sigma, St. Louis, MO) and
pokeweed (Phytolacca Americana lectin; Sigma, St. Louis, MO). Following a 24-hour mitogen
incubation period, T lymphocytes were isolated directly from the peripheral blood using a Dynal
T cell negative isolation kit (Invitrogen, Canoga Park, CA) and resuspended in complete media.
Activated T lymphocytes were confirmed and isolated using flow cytometry (Appendix C). This
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purely activated (and antibody free) T cell population was then cultured at 37°C in 5% CO2 in
multi-well plates in complete media containing recombinant interleukin 2 (50U/ml; Becton
Dickinson, San Jose, CA). Negative control samples were cultured in parallel and consisted of T
lymphocytes pretreated with Mitomycin C (Sigma, St. Louis, MO; 0.025 mg of Mitomycin C
(0.5 mg/ml) to each 1 ml of cell suspension) for 20 minutes. T lymphocyte cultures were
continued for 72 hours with daily viability testing, daily RS analysis, and mAb staining at 48 and
72 hours.
7.2.2- Monoclonal Antibody Staining

Representative aliquots of mitogen-activated T lymphocytes were collected at 48 and 72
hours following initial stimulus and washed three times using PBS. All cells collected at each
time period were stained with a 4’,6-diaminidino-2-phenylindole (DAPI; Thermo Fisher
Scientific, Rockford, IL) nuclear stain that was contained in an anti-fade solution. In addition,
cells were divided into two groups at each time interval. The first group was treated with
paraformaldehyde (Sigma, St. Louis, MO) and incubated overnight with the transient cell surface
mAb, CD69 (Becton Dickinson, San Jose, CA). The second group was treated with
permeabilizing solution (Becton Dickson, San Jose, CA) and incubated overnight with the
intracellular antibody cocktail containing a CD25/CD71 (Becton Dickson, San Jose, CA)
mixture with subsequent fixing with paraformaldehyde. Cells were viewed using a Nikon Eclipse
TE 2000-U inverted microscope with images being captured and processed using Metavue 6.2r5
software (Downingtown, PA).
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7.2.3 Raman Spectroscopic Analysis

Raman spectroscopic analysis was carried out daily on non-antibody bound lymphocytes.
Spectra from the 48 and 72 hour time points were compared to mAb staining data derived from
methods described previously. Prior to analysis, all samples were washed with PBS. Cells were
allowed to settle within the analysis reservoir placed on a leveled microscope stage. Only
rounded, non-adhered, isolated and individualized T lymphocytes were selected for study. Each
sample was analyzed using an identical protocol and spectroscopic parameters. Using an
enhanced video imaging system, T lymphocytes were aligned in the laser target area so that the
focus point was centered on the lymphocyte. Images were captured before and after each
measurement with no noted cell shifting or destruction observed. Wire 2 software (Renishaw plc,
Old Town, United Kingdom) was utilized in conjunction with the Raman system for quantitative
measurements. RS measurements were conducted using a Renishaw InVia 2000 microscopespectrometer with a Leica 63X water immersion objective (NA= 1.20). T lymphocytes were
analyzed using a 514.5 nm (green) Ar+ excitation wavelength. Laser power was set at 50% (8-12
mW) for a 2-4 µm laser spot size. Spectra were collected in the backscattering geometry with a
10 second integration time over a range of 500 to 1700 cm-1. The spectral resolution was ~ 4
cm-1.
7.2.4- Statistical Analysis

Prior to statistical analysis, all data were checked for various types of noise as described
in section 5.2.5. Student’s t-test was utilized to further quantify differences in peaks. The data
were analyzed for the presence of various independent groups using DFA. Graphical and
quantitative analysis of data was accomplished using SPSS version 15 software (Statistical
Software, Chicago, IL).
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Chapter 7.3- Results

Forty-eight hours following mitogen stimulation, representative T lymphocytes were
stained for activation markers according to the procedures stated above. In addition, 50 T
lymphocytes at this same time point were analyzed using RS. All lymphocytes included in this
analysis were verified to be intact and non-apoptotic. In addition, DAPI staining revealed that
cells analyzed were nucleus containing and viable (Figure 23, Panel A and D).
High expression of the transient CD69 cell surface receptor was evident when assessing
qualitative antigen expression at 48 hours via mAb staining (Figure 23, Panel B). However, T
lymphocytes at the 72 hour time point showed no appreciable binding of the fluorescent tag
(Figure 23, Panel E.). Moreover, 48 hour RS- analyzed T lymphocytes demonstrated a
significant peak difference at the 1585 cm-1 position (Figure 24). The 48 hour samples had a
mean peak magnitude of 2899.23 ± 165.38 compared with 2364.39 ± 229.62 for the 72 hour
samples. For the 48 hour samples, this represented a 22% (p = 0.01) increase in peak magnitude
at this position.
There was a precipitous increase in the expression of CD25/CD71 from 48 to 72 hours
(Figure 23, Panels C and F). In addition, the corresponding RS-analysis demonstrated two
significant peak differences at the 903 cm-1 and 1449 cm-1 positions (Figure 25). There was an
18% (p = 0.04) and 11% (p = 0.001) increase in peak magnitudes at the 903 cm-1 and 1449 cm-1,
respectively.

71

A

B

D

E

C

F

Figure 23. Representative 48 hour (Panels A-C) and 72 hour (Panels D-F) antibody stained mitogen activated T
lymphocytes. Panels A and D- DAPI stain. Panels B and E- CD69 stain (FITC).
Panels C and F- CD25/CD71 stain (PE).
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Figure 24. Mean (n = 50) Raman spectral changes at 48 hours with accompanying antibody staining results for 48
hours and 72 hours- (insets A and B, respectively). Arrow indicates significant peak difference at 48 hours. Note:
for additional peaks associated with activation please see Figure 12A and 15A.
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Figure 25. Mean (n = 50) Raman spectral changes at 72 hours (red) with accompanying antibody staining results for
48 hours and 72 hours- (insets A and B, respectively). Arrows indicate significant peak changes at 72 hours. Note:
for additional peaks associated with activation please see Figure 12A and 15A.
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Chapter 7.4- Discussion

The goal of this study was to link RS spectral changes with a direct method of measuring
the biomolecular process of cell surface receptor up-regulation and expression. At 48 hours, the
T lymphocyte is considered to be in the “early” phase of activation [10]. This early activation
resulted in transient CD69 expression detected by mAb staining panels. This was coupled with
RS signature changes at the 1585 cm-1 position, consistent with carbohydrate (C-O-C
deformation) and nucleic acid (Guanine, Adenine) turnover [11] (Appendix B). Conversely,
“late” T lymphocyte activation was dominated by the up-regulation of CD25 and CD71 [10].
The expression of CD25 and CD71 was marked by a significant qualitative increase in the
intensity of the fluorescent tag which was matched by RS signature changes at the 903 cm-1 and
1449 cm-1 peak positions. These Raman shifts were consistent with conformational changes in
protein (C-C backbone stretching, α helix changes), carbohydrate (CH deformation), and lipid
(CH2 bending) molecular events [11] (Appendix B). The specific ramifications of the C-O-C
deformation at 48 hours and the C-C backbone stretching and alpha helix changes at 72 hours
will be further discussed on Chapter 8.
This foundational study looked at the molecular events following activation by a mitogen
(i.e. super-antigen). By tracking the up- and down-regulation of receptors through mAb binding
which is dictated by Fab domain specificity, we were able to mark conformational changes in the
cell surface topography. We were then able to couple these conformational changes with Raman
shifts that occur within the same time frame. The next chapter will explore how alterations in 3D
structure can affect Raman scattering.
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CHAPTER 8- CONCLUSION AND FUTURE DIRECTIONS
Chapter 8.1- Conclusion

The immune system reflects a duality of requirements dictated by the need to remain
relatively conserved in many of its activation pathways, while maintaining a high level of
specificity for a particular antigen. This notion has been thoroughly demonstrated through
studies involving the MHC, TCR, and other cell surface receptors involved in the activation
process [1]. Our series of studies suggest that when examining the array of receptors expressed
during varying methods of activation using the RS system, a duality of conservation and
specificity is articulated via unique Raman spectroscopic shifts. When analyzing the ratios of the
1182:1195 cm-1 peaks, we found a similar shift in the alloreactive, CD3/CD28-activated, and
mitogen-activated samples. However, these shifts were not present in the inactivated or resting T
lymphocyte populations. This shift likely represents a change in light scattering that is a result of
a conformational change in the CD3-TCR 3D structure and/or adjacent membrane, which is
necessary for all forms of activation regardless of the initial stimulus. To further explore the link
between conformational changes in 3D structure and characteristic Raman shifts observed in our
study, let us consider the structural immunology work carried out by Lee and colleagues [2] who
reported on the specific TCR residue changes responsible for driving alterations in 3D structure.
The authors compared the contributions of residues involved in the binding of the TCR to selfversus allo-MHC molecules. They found that the self- and allo-MHC binding residues differed at
25 of the 41 positions within the CDR2 and CDR3 regions of the variable α and β domains. Of
these two regions, the CDR3 had the greatest influence on binding differences which was
attributed to the increased mobility of the CDR3 containing loop [2]. These residues were further
categorized based on whether they were significantly, intermediately, or non-significantly
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involved in binding (Figure 26). This study illustrates the key principle that even individual
residue differences in the binding domain of the TCR can convey significant changes in binding
specificity, which is ultimately manifested as changes in receptor form.

Figure 26. Differences in 3D confirmation and receptor structure dictate whether the TCR will bind to
self- versus allo-MHC molecules. Residues in red indicate those with the greatest effect on binding; Pink residues
have intermediate effect on binding; Yellow residues have negligible effect of binding. Blue lines represent the
binding orientation of antigen peptide (curved line) and two domains of the MHC (coiled lines). Note the differences
in distribution and number assignments of the red residues [2].
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In addition to factors influencing TCR form, the authors dealt with function. They
showed that T lymphocyte activity was reduced by upwards to 90% when single site mutations
were introduced at eight amino acid residues in the variable alpha and beta domains. This
observation aptly demonstrates that subtle changes in amino acid residues in the exposed portion
of the TCR can dramatically affect function. When these aforementioned concepts of form and
function are juxtaposed and placed in the context of our study which analyzed the
conformational changes in, and variations of, the 3D structure of the TCR using RS, we find a
link between the structural Immunobiology and changes in Raman scattering (Figure 27).
Published peak assignments [3-6] for the 1182:1195 cm-1 position, which were shared by all
activated T lymphocytes, suggests that the observed shifts represent changes in tyrosine and
phenylalanine, two amino acids that are important in the dimerization of the TCR- CD3 complex
via phosphorylation by Zap-70. They may also represent residues within the prominent binding
domain of the TCR that were exposed by conformational changes in the aforementioned CDRs
of the α and β chains [7] .

T Cell
activation
via binding
to the TCR

Change in
binding
domain
residues

Conformation
al change in
3D structure

Change in
Raman
scattering

Figure 27. Proposed structural etiology for observed Raman shifts and subsequent
activation signature differences.

T cell
activation
signatures
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The Raman shift at the 1182:1195 cm-1 position, which was shared by all activated T
lymphocytes, can be contrasted with shifts occurring at 903 cm-1, 1093 cm-1, and 1449 cm-1, that
were specific to CD3/CD28 and mitogen-activated lymphocytes, but not the alloreactive T
lymphocyte population. Moreover, signature differences at positions 1031 cm-1, 1155 cm-1, and
1326 cm-1 were specific only to CD3/CD28-activated lymphocytes, while position 1585 cm-1
was unique only to the mitogen-activated samples. These differences can be explained by the
scattering changes that occur as a result of de novo up-regulation of CD25, CD69, and CD71.
These structures dramatically change the topography of the cell surface and thus significantly
alter the way that light scattering occurs and because the specific 3D structure of the particular
receptor expressed is unique to that receptor, it leads to a unique spectral shift that contributes to
the entire activation signature. By coupling published peak assignment data [3-6] with shifts
noted in each of the activated T lymphocyte groups, we observed that CD3/CD28 and mitogen
activated T lymphocytes underwent C-C backbone, alpha helix, and C-H deformation changes in
protein structures. Due to the mixed contribution that the CD25 and CD71 receptors provide to
light scattering and their similar expression patterns (i.e. timing and type of stimulus triggering
their expression), separating and assigning individualized proteinaceous changes is difficult.
However, in the case of the CD69 receptor, our expression kinetics data (Chapter 7) provides a
method for this individualized assignment. The transient nature of CD69 expression also leads to
a transient state of its Raman scattering contribution. Based on this observation, we can conclude
that the CD69 receptor demonstrated a unique shift at 1585 cm-1 that resulted from C-double
bond-C phenylalanine and tyrosine residue changes in its protein structure.
When the observed Raman shifts for all T lymphocyte groups are taken as a collective we
find that there were significant changes in lipid, carbohydrate, protein, and nucleic acid groups
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that defined differences between activated and non-activated T lymphocytes. The presence of
this array of biomolecular materials involved in the process of activation can be clearly
accounted for by the requirements and results of DNA transcription, translation, processing of
cell surface receptors in the rough endoplasmic reticulum and Golgi apparatus, delivery and
membrane docking of lipid-lined vesicles containing refined receptors, and expression of these
carbohydrate-covered receptors on the cell surface. However, from a spectroscopic point of
view, it would be expected that if our RS analysis was confined solely to the external surface of
the cell, there would be shifts that encompassed all categories except nucleic acids, for this
content does not exist outside of the intracellular nucleus/ribosome context. The presence of
these shifts involving nuclear material seen at different positions in all forms of activated T
lymphocytes can be attributed to the resolution and penetration depth of the laser used in our
analysis. The diameter of a T lymphocyte is ~ 10-12 µm while the laser spot size used in our
experiments was ~ 3 µm. Although this spot size allowed for accurate analysis of the T
lymphocyte, the shape and proportional dimensions of laser diameter to cell diameter yielded a
resulting spectrum that was a composite of Raman shifts from receptor groups (carbohydrates
and proteins), adjacent membrane (lipids), and sub-membranous regions (nucleic acids) (Figure
28). This mixed contribution is the basis of our activation signatures.
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Figure 28. Laser sampling area of T lymphocyte surface and subsurface that includes multiple receptor groups,
proteins, and lipids.

RS-based activation signatures reflect the biomolecular diversity resulting from the
particular form of stimulation and are the basis of how a RS system could detect activated
lymphocytes with high sensitivity and specificity. The value of this high sensitivity and
specificity is two-fold. First, it provides an avenue to transition away from the paradigm of using
invasive biopsies to confirm the diagnosis of AR and also provides an alternative to protocol
biopsies to detect SCAR. Second, RS detection of AR offers a modality that could significantly
reduce the delay in AR diagnosis. Under the current diagnostic algorithm, delays in treatment are
created due to the need to eliminate other potential causes of serum creatinine elevations, thus
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potentially allowing further histologic damage to the nephrons of transplanted grafts that
continue to be in limited supply.
The overall conclusion of this dissertation is that with further refinement, RS can serve as
a technological tool capable of detecting activated T lymphocytes (sensitivity) in urine or blood
while offering additional information as to the particular method of nonspecific or MHCrestricted activation (specificity) based on the biomolecular and structural modeling of cell
surface receptors.
Chapter 8.2- Future Directions

To gain further information concerning the biomolecular process that occurs during all
stages of T lymphocyte activation, multi-spectral RS could be utilized in conjunction with a live
cell imager, a device designed to allow for enclosed cell culturing and continuous RS analysis.
This experimental design could effectively track Raman shifts from the very early steps of DNA
transcription to the maturation of cell surface receptors and clonal expansion. This system could
be enhanced with use of atomic force microscopy (AFM), a device that passes an ultrasensitive
lever (cantilever) over a measured substance. The cantilever is designed to deflect according to
surface patterning of the measured substance and thus provide precise topographic data. AFM
has a resolution of < 1nm and can directly quantify the conformational change in a single
receptor thereby allowing data collection regarding the evolution of individual receptors in
response to an activation stimulus [8-10]. This high resolution can provide an alternative
approach to the comprehensive analysis (receptor, adjacent membrane, and sub-membranous
region) that a 4 µm laser spot size currently provides.
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The potential applications of RS-based T lymphocyte analysis in the medical arena are
vast. One such application could be the development of a comprehensive panel of clinically
relevant signatures based upon viral (CMV and BK virus), fungal (Candida), and bacterial (E.
coli) stimuli. These pathogens have a particularly devastating effect on graft survival in the
transplant population. A rapid, accurate, noninvasive test for these pathogens (and others) would
prove invaluable in the treatment of infectious diseases.
Another application involves using RS as a functional T cell assay. Based upon the
notion that the true metric of adequate immunosuppressive therapy is the functional suppression
of T lymphocyte activation measured at the level of the T cell, the RS system could be used to
titrate immunosuppressant levels in an individualized way. Currently, dosing of powerful and
sometimes toxic immunosuppressant medication is based on semi-standardized drug target
levels, which often are limited by inter- and intra-patient variability and side-effect tolerance. RS
could be used to rapidly assess the real-time immunologic temperament of T cells based on their
activation state within the guise of the individual patient’s current medication regimen. This
would allow clinicians to decrease dosages to levels that are functionally adequate for each
particular patient and thus avoid unwanted dose-related side effects while substantially reducing
costs.
In addition to transplant immunology and infectious disease, T lymphocyte activation
plays a pivotal role in oncology. Whether it is melanoma, hematologic cancers, or the various
solid organ, connective or soft tissue malignancies, T cell changes may provide one of the
earliest clues to the presence of these disease states. RS analysis of an appropriate oncological
model could add to the growing body of knowledge concerning biomarkers directed at early
cancer detection.
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This dissertation outlines the use of RS in the resolution and modeling of cell surface
receptor differences that define T lymphocyte activation. The accurate detection of T lymphocyte
activation within a biomatrix is the foundational step toward the development of a noninvasive
tool capable of accurately detecting AR in real-time within the clinical setting.
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APPENDICES
Appendix A. Banff 97 Criteria and Histologic Phenotype [1, 2]
Grade

Pathological Description

Histology

Tubulointerstitial infiltrates
IA
>25% of parenchyma with foci
of moderate tubulitis (arrow)

IB

IIA

IIB

III

Significant interstitial infiltration
(^) with foci of severe tubulitis
(arrow)

Mild to moderate intimal arteritis

^

•

Severe intimal arteritis
comprising the luminal areanearly complete occlusion (*)

*

Transmural arteritis and/or
dilated vessels (#) with arterial
fibrinoid change and necrosis of

#

medial smooth muscle cells (•)

•
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Appendix B- Raman Spectroscopic Peak Assignments [3-5]
Peak
Assignment
-1

(cm )
618-621

Protein: C-C twist phenylalanine

640-645

Protein: C5 stretch, C-C twist Tyr

666-667

Nucleic Acid: T,G, tyrosine, G backbone in RNA

717

Lipids: CN+(CH3)3 stretch

725-729

Nucleic Acid: Adenine breathing

729

Nucleic Acid: Adenine

746

Nucleic Acid: Thymine breathing

760

Protein: Ring breath tryptophan

782

Nucleic Acid: uracil, cytosine, thymine ring breathing

788

Nucleic Acid: O-P-O stretching, uracil
Protein: C-C backbone stretching α -helix;

903-937

Carbohydrates: C-O-C glycos. Nucleic Acid O-P-O asym. stretch
1002-1005

Protein: Sym. Ring breathing phenylalanine

1031-1033

Protein: C-N stretching, C-H in-plane phenylalanine
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1053

Protein: C-N stretching, C-O stretching
Nucleic Acid: phosphate stretching; Lipids: chain C-C stretching;

1069-1095

Carbohydrates: C-O, C-C stretching
1126-1128

Protein: C-N stretching

1155-1158

Protein: C-C, C-N stretching

1175

Protein: C-H bending tyrosine
Protein: C-H bending, amide III, tyrosine, phenylalanine;

1182-1195

Nucleic Acid: adenine, thymine
1208

Nucleic Acid: adenine, thymine; Protein: Amide III

1319-1326

Nucleic Acid: guanine; Protein: C-H deformation

1342

Nucleic Acid: adenine, guanine; Protein: C-H; Carbohydrates: C-H deformation
Nucleic Acid: guanine, adenine, C-H deformation; Protein: C-H; Lipids: C-H

1420-1480

deformation; Carbohydrates: C-H deformation
Nucleic Acid: guanine, adenine
1578-1585

Protein: C-double bond-C phenylalanine, tyrosine
1607

Protein: C-double bond-C phenylalanine, tyrosine

1655-1680

Protein: Amide I; Lipids: C-double bond-C stretching
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Appendix C. Flow Cytometry Directed Verification of T –lymphocyte Activation Status.
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Appendix C (continued). Flow Cytometry Directed Verification of T –lymphocyte
Activation Status.
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Appendix D. Raw data images from cellular preparations

94

Appendix D (Cont.). Raw data images from cellular preparation

Immunomagnetic bead directed toward B lymphocytes were used to purify T lymphocyte
samples. Note the B lymphocytes (~10 micrometers) are attaching to the pro-B lymphocyte
antigens coating the bead which is several magnitudes larger.
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Appendix E. Reference and Control Raman Spectra
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Appendix F. Human Investigation Committee Approval
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Appendix G. List of Key Abbreviations


APC- Antigen Presenting Cell



AR- Acute Rejection



CAN- Chronic Allograft Nephropathy



CMV- Cytomegalovirus



DFA- Discriminant Function Analysis



ESRD- End Stage Renal Disease



HIC- Human Investigation Committee



HLA- DR- Human Leukocyte Antigen –DR



Ig- Immunoglobulin



mAb- Monoclonal Antibody



MHC- Major Histocompatibility Complex



MLC- Mixed Lymphocyte Culture (also referred to as Mixed Lymphocyte Reaction
(MLR)



RS- Raman Spectroscopy



PCA- Principal Component Analysis



PCR- Polymerase Chain Reaction



SCAR- Subclinical Acute Rejection
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Despite the advances made in the area of kidney transplantation, the disparity between
the demand for and supply of available donated organs remains a dominant and unresolved issue.
Given the paucity of available renal allografts, the preservation of existing grafts is vital. One
factor that has negatively impacted renal allograft survival is acute rejection (AR). Traditionally,
kidney transplant centers have used elevations in serum creatinine as a screening tool for
detecting AR. However, with its diagnostic delay, low sensitivity, and low specificity, serum
creatinine has proven to be an unreliable and problematic bio-marker. AR is an activated T
lymphocyte driven process that leads to graft dysfunction and possible loss. The activation state
of T lymphocytes is determined by the specific cell surface receptor composition present. A
technologic tool that could resolve these receptor differences could detect T lymphocyte
activation and thus provide a diagnostic modality for AR. Raman spectroscopy (RS), a laserbased technology that is able to characterize substances based on molecular vibrational
signatures, represents this modality. Using T lymphocytes isolated from human peripheral blood
and clean-catch urine we investigated three aspects of T lymphocyte activation using a modified
RS system. First, we explored the sensitivity (the ability to detect activation) of a RS-based
system by analyzing mixed lymphocyte reacted (MLR), mitomycin C inactivated, and resting T
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lymphocytes at 785nm and 514.5nm wavelengths. Second, the specificity (the ability to
distinguish T cells activated by different stimuli) of the system was determined by comparing the
signatures of MLR and CD3/CD28-activated T lymphocytes. Third, we analyzed the
biomolecular events that conveyed the spectral changes detected by RS. This was carried out by
coupling RS analysis of Mitogen-activated T lymphocytes with antigen expression kinetic
studies designed to quantify the intensity and timing of cell surface receptor up-regulation. We
found that there were significant RS signature differences between the MLR and non-activated
(inactivated and resting) T lymphocytes while there was only a trend toward differences seen
between the resting and inactivated cellular populations. When analyzing MLR versus
CD3/CD28-activated cells, both samples differed from the inactivated and resting groups and
demonstrated differences in Raman shifts at multiple foci when compared with one another.
Receptor expression kinetics of mitogen-activated T lymphocytes analyzed at the early and late
phases of activation showed differential antibody immuno-fluorescent intensity. This correlated
with spectral differences at defined peaks. Moreover, when analyzing all forms of activation (i.e.
MLR, CD3/CD28, or mitogen) there were conserved and reproducible signature changes
regardless of mode of activation which supports the notion that there are receptor and receptor
moiety changes that are required in all forms of T lymphocyte activation. This dissertation
outlines the use of RS in the resolution and modeling of cell surface receptor differences that
define T lymphocyte activation. The accurate detection of T lymphocyte activation within a
biomatrix is the foundational step toward the development of a noninvasive tool capable of
accurately detecting AR in real-time within the clinical setting.
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